Praxis reports Q2 2026 results, mid-cycle FDA meetings clear for two lead drugs
The FDA identified no major safety or efficacy concerns for ulixacaltamide or relutrigine, with PDUFA dates of January 29, 2027 and December 27, 2026, respectively.
SEC filing